Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem-vaborbactam vs piperacillin-tazobactam in Chinese patients with complicated urinary tract infection
CTR20231032Phase 3Completed
- Sponsor
- Menarini Group
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of meropenem + vaborbactam in complicated urinary tract infection (cUTI), pyelonephritis, sponsored by Menarini Group. Started Apr 2023; status: completed.
02
Drugs
meropenem + vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on CTR20231032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231032.